Newron Pharmaceuticals S.p.A.
NP5
Rankning i aktier
#17693
Newron Pharmaceuticals SpA is a biopharmaceutical enterprise headquartered in... Newron Pharmaceuticals SpA is a biopharmaceutical enterprise headquartered in Bresso, Milano, with a dedicated team of 24 full-time employees. The company's core mission is the discovery and advancement of innovative pharmaceutical products, particularly focusing on new therapies for Central Nervous System (CNS) disorders and pain management. Among its leading candidates, safinamide is currently undergoing Phase III clinical trials for the treatment of Parkinson's disease. Additionally, ralfinamide is being developed as a potential therapy for neuropathic pain. The firm's pipeline further includes a range of projects at various preclinical and clinical development stages, such as HF0220 for neuroprotection, NW-3509 for schizophrenia, and pruvanserin and sarizotan for other CNS conditions.
Aktiekurs
$10.40
Marknadsvärde
$212.64M
Förändring (1 dag)
1.09%
Förändring (1 år)
-41.83%
Land
IT
Handel Newron Pharmaceuticals S.p.A. (NP5)
Kategori
Healthcare
Aktiekurshistorik för Newron Pharmaceuticals S.p.A. (NP5)
Högsta slutkurs: $10.24 den 2026-10-01
Lägsta slutkurs: $31.91 den 2015-07-01
Lägsta slutkurs: $31.91 den 2015-07-01
Aktiekurshistorik för Newron Pharmaceuticals S.p.A. från 2015 till 2026
Årlig aktiekursutveckling
| År | Prestanda |
|---|---|
| 2026 (TTM) | -24.57% |
| 2025 | 182.46% |
| 2024 | 72.12% |
| 2023 | 283.57% |
| 2022 | -24.03% |
| 2021 | -24.86% |
| 2020 | -62.21% |
| 2019 | -18.66% |
| 2018 | -28.88% |
| 2017 | -55.22% |
| 2016 | -5.77% |
| 2015 | 0.00% |
Aktiekurs för liknande företag eller konkurrenter
| Företag | Aktiekurs | Förändring 1år% | Land |
|---|---|---|---|
| $536.13 | 25.72% |
US
|
|
| $200.12 | 645.31% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $291.76 | 2.51% |
BE
|
|
| $880.01 | 8.09% |
NL
|
